Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication

  • Arch Virol. 2017 Sep;162(9):2847-2853. doi: 10.1007/s00705-017-3436-8.
Lei Cai  1 ,  Yajie Sun  1 ,  Yabin Song  1 ,  Likun Xu  1 ,  Zhuchun Bei  1 ,  Dongna Zhang  1 ,  Yuanyuan Dou  1 ,  Hongquan Wang  2
Affiliations
  • 1. State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Science, Beijing, 100071, China.
  • 2. State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Science, Beijing, 100071, China. [email protected].
PMID: 28597088 DOI: 10.1007/s00705-017-3436-8
Abstract

Since 2015, 69 countries and territories have reported evidence of vector-borne Zika virus (ZIKV) transmission. Currently, there are no effective licensed vaccines or drugs available for the treatment or prevention of ZIKV Infection. We tested a series of compounds for their ability to inhibit ZIKV replication in Cell Culture. The compounds in T-705 (favipiravir) and T-1105 were found to have Antiviral activity, suggesting that these compounds are promising candidates for further development as specific Antiviral drugs against ZIKV.

Keywords
Broad-spectrum antiviral drugs; T-1105; T-705; Zika virus (ZIKV).
Products